Pharmacogenomic Research in Korean Patients With Hepatitis C

Sponsor

Inje University (Other)

Overall Status

Completed

CT.gov ID

NCT01453244

Collaborator

(none)

373

Enrollment

Location

Duration (Months)

18.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.

Condition or Disease	Intervention/Treatment	Phase
Chronic Hepatitis C

Study Design

Study Type:

Observational

Actual Enrollment :

373 participants

Observational Model:

Cohort

Official Title:

Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C

Study Start Date :

Jul 1, 2011

Actual Primary Completion Date :

Mar 1, 2013

Actual Study Completion Date :

Mar 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
SVR group A patients who achieved SVR (sustained virologic response)
non-SVR group A patients who not achieved SVR (sustained virologic response)

Outcome Measures

Primary Outcome Measures

Sustained virological response (SVR) [24 weeks after the end of treatment]
Undetectable HCV RNA in serum ( <15 IU/ml ) 24 weeks after the end of treatment